ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.


  1. 1.

    Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2018; Epub ahead of print.

  2. 2.

    Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2018. Accessed: May 21, 2019.

  3. 3.

    Mancher M, Leshner AI. Medications for Opioid Use Disorder Save Lives. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder: Washington (DC): National Academies Press (US); 2019 Mar. Accessed July 1, 2019.

  4. 4.

    Sordo L, Barrio G, Bravo MJ, Indava BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

  5. 5.

    Frank CJ, Kushner SE, Doran DA, Stehr-green J. Mandatory reporting of fatal and nonfatal opioid overdoses in a rural public health department. Am J Public Health. 2018;108:1646–8.

  6. 6.

    Kresina TF, Lubran R. Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health. 2011;8:4102–17.

  7. 7.

    Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27:669–76.

  8. 8.

    Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230–42.

  9. 9.

    Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–35.

  10. 10.

    Drug Enforcement Administration Office of Diversion Control Drug & Chemical Evaluation Section: Buprenorphine. Accessed 1 Feb 2019

  11. 11.

    Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of comparative clinical effectiveness, cost-effectiveness and guidelines [internet]. Ottawa (ON): Canadian agency for Drugs and Technologies in Health; 2016 Sep 2.

  12. 12.

    Lee S, Klein-schwartz W, Welsh C, Doyon S. Medical outcomes associated with nonmedical use of methadone and buprenorphine. J Emerg Med. 2013;45:199–205.

  13. 13.

    Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2018.

  14. 14.

    Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428–50.

  15. 15.

    Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10:209–19.

  16. 16.

    Lowfall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8:315–26.

  17. 17.

    Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45.

  18. 18.

    Marteau D, Mcdonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open. 2015;5:e007629.

  19. 19.

    Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis - buprenorphine myths and realities. N Engl J Med. 2018;379:1–4.

  20. 20.

    Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35:108–12.

  21. 21.

    Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. Subst Abus. 2018;39:263–5.

  22. 22.

    Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M, Baston K, et al. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abus Treat. 2018;93:19–25.

  23. 23.

    Lowenstein M, Kilaru A, Perrone J, Meisel Z, Delgado MK. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. [published online ahead of print February 18 2019]. Am J Emerg Med. 2019.

Download references

Author information

Correspondence to Ryan Marino.

Ethics declarations

Conflict of Interest



While individual practices may differ, this is the position of the American College of Medical Toxicology at the time written, after a review of the issue and pertinent literature.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supervising Editor: Mark B. Mycyk, MD

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Marino, R., Perrone, J., Nelson, L.S. et al. ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder. J. Med. Toxicol. 15, 307–309 (2019).

Download citation


  • Buprenorphine
  • Waiver
  • X-waiver
  • Opioid use disorder
  • Opioid agonist therapy